Clinical Research Directory

Inclusion Criteria: * Histologically confirmed carcinoma of the prostate (biopsy results with 12 months of enrollment) * Intermediate risk as defined by NCCN criteria * Conventional imaging (bone scan and abdominal pelvic computed tomography) is mandatory for NCCN unfavourable intermediate risk prostate cancer patients with PSA \> 10. Negative nodal, skeletal or visceral metastases within 16 weeks of enrollment (for patients requiring staging). Alternatively, patients with no signs of extra-prostatic disease on PSMA-PET scans are also candidates for this trial * ECOG performance status 0-1 * Willing to give informed consent to participate in this clinical trial * Able and willing to complete QOL questionnaires Most responsive physician definition if androgen deprivation therapy will be used (only allowed for NCCN unfavourable intermediate risk prostate cancer) Exclusion Criteria: * Estimated prostate volume \> 60cc (volume based on transrectal ultrasound) * Prior TURP * Prior prostate cancer treatment, including 5-alpha reductase inhibitor treatment * Low, high or very high-risk disease as per NCCN guidelines * Connective tissue disease or inflammatory bowel disease * Contraindication to prostate microUS * Men with double hip prostheses * Contraindication for MRI (i.e. non-compatible stent, pacemaker, prosthesis etc.) * Anticoagulation medication (if unsafe to discontinue for fiducial marker insertion) * Diagnosis of bleeding diathesis